迈克生物(300463) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 was ¥1,048,907,406.74, a decrease of 2.62% compared to the same period last year, while year-to-date revenue increased by 18.97% to ¥3,009,280,740.63[5] - Net profit attributable to shareholders for Q3 2021 was ¥264,476,232.47, up 3.39% year-on-year, with a year-to-date net profit of ¥796,158,158.88, reflecting a 40.65% increase[5] - The basic earnings per share for Q3 2021 was ¥0.4751, representing a 3.33% increase, while year-to-date earnings per share rose by 40.71% to ¥1.4326[5] - Total operating revenue for the current period reached ¥3,009,280,740.63, an increase of 18.9% compared to ¥2,529,544,954.27 in the previous period[29] - Net profit attributable to the parent company was ¥796,158,158.88, up 40.6% from ¥566,072,179.01 in the same period last year[34] - The company reported a comprehensive income total of ¥833,100,297.86, compared to ¥588,606,995.55 in the previous period, marking a 41.6% increase[34] - The basic earnings per share for the current period was ¥1.4326, compared to ¥1.0181 in the previous period, indicating a significant improvement[34] Cash Flow - The company's cash flow from operating activities for the year-to-date period was ¥878,776,421.53, showing a significant increase of 141.13%[11] - The net cash flow from operating activities for the current period is ¥878,776,421.53, a significant increase from ¥364,433,586.06 in the previous period, representing a growth of approximately 141.3%[39] - The total cash inflow from operating activities is ¥3,311,955,563.48, compared to ¥2,780,910,428.16 in the previous period, indicating an increase of about 19.1%[36] - Cash outflows from operating activities totaled ¥2,433,179,141.95, slightly up from ¥2,416,476,842.10, reflecting a marginal increase of 0.7%[36] - The net cash flow from investing activities is -¥409,468,914.15, worsening from -¥181,583,484.43 in the previous period[39] - Cash inflow from financing activities decreased to ¥1,005,667,444.25 from ¥1,333,875,959.73, a decline of approximately 24.5%[39] - The net cash flow from financing activities is -¥464,180,095.45, compared to -¥139,975,825.96 in the previous period, indicating a deterioration in financing cash flow[39] - The ending balance of cash and cash equivalents is ¥587,616,384.50, up from ¥470,707,986.10, showing an increase of about 24.8%[39] Assets and Liabilities - Total assets as of September 30, 2021, were ¥6,634,455,203.04, an increase of 4.23% from the end of the previous year[5] - The company's equity attributable to shareholders increased by 8.83% to ¥4,131,797,163.29 compared to the end of the previous year[5] - The company reported a significant increase in asset disposal gains of 686.48% year-on-year, amounting to ¥3,925,831.69[11] - The total assets of the company as of September 30, 2021, amounted to ¥6,634,455,203.04, an increase from ¥6,364,982,648.45 as of December 31, 2020[20] - The total liabilities decreased to ¥3,999,742,230.31 from ¥4,000,000,000, indicating a slight reduction[22] - Total liabilities decreased to ¥2,265,933,266.48 from ¥2,359,537,132.90, a reduction of approximately 4%[29] - The company's total operating costs were ¥1,993,276,148.82, which is an increase of 11.6% from ¥1,786,643,304.18 in the previous year[29] Research and Development - Research and development expenses for the year-to-date period reached ¥148,770,233.37, a 60.73% increase compared to the previous year, indicating a strong commitment to product development[11] - Research and development expenses increased to ¥148,770,233.37, representing a 60.8% rise from ¥92,561,483.33 in the previous year[29] Shareholder Information - The company reported a total of 164,063,304 shares with restricted trading, with 9,021,111 shares released during the period[19] - The number of shares held by the top ten shareholders includes significant holdings such as 51,046,726 shares by Tang Yong[16] Other Financial Metrics - The company's cash and cash equivalents were reported at ¥608,821,058.49, slightly down from ¥612,065,315.96 in the previous year[20] - Accounts receivable decreased to ¥1,983,891,687.64 from ¥2,020,529,599.32 year-over-year, indicating a reduction of approximately 1.8%[20] - Inventory increased to ¥1,129,744,474.27 from ¥1,074,837,340.90, reflecting a growth of about 5.1%[22] - The company's non-current assets totaled ¥2,590,712,972.73, up from ¥2,339,770,779.54, representing an increase of approximately 10.7%[22] - The company has a total of 4,043,742,230.31 in current assets, showing a marginal increase from 4,025,211,868.91[22] - The company’s short-term borrowings decreased to ¥768,444,577.76 from ¥921,547,655.36, reflecting a reduction of approximately 16.6%[22] - Minority interests increased to ¥236,724,773.27 from ¥208,742,321.89, reflecting a growth of 13.4%[29] Audit Information - The company has not undergone an audit for the third quarter report[49]